EUCTR2005-004478-26-SE
Active, not recruiting
Not Applicable
Effects of growth hormone treatment to patients with partial growth hormone deficiency, with special emphasis on acute phase proteins and pro-inflammatory cytokines.
DrugsNorditropin SimpleXx
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Karolinska universitetssjukhuset
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Verified GHD (GH secretion \<3µg/L after stimulation tests) or GHI (GH secretion 3\-7µg/L after stimulation tests).
- •2\. Between 18 and 60 years old.
- •3\. Informed consent obtained before any trial\-related activities (trial\-related activities are any procedure that would not have been performed during normal management of the subject).
- •4\. Stable substitution of other hormones for a period of 6 months.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\.Known or suspected allergy to GH preparation.
- •2\.Previous participation in this trial.
- •3\.Participation in other clinical trials within the past three months.
- •4\.GH treatment within the last year.
- •5\.Malignancy or other serious diseases (ex severe cardiovascular diseases (NYHA 3\-4\), severe infections).
- •6\.Sex hormone treatment initiated within the last year.
- •7\.Expected inability to comply with trial protocol.
- •8\.Pregnancy.
- •9\.Lactation.
- •10\.Diabetes mellitus
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy and safety of growth hormone treatment in short children born small for gestational age; effects of growth hormone levels on growth, insulin sensitivity and body compositioSmall for gestational age (SGA), children with persistent short staturePregnancy and ChildbirthSlow foetal growthISRCTN65230311Erasmus Medical Center (The Netherlands)157
Not yet recruiting
Phase 3
Investigating the results of adding growth hormone to the ovulation stimulation regimen in microinjection and In Vitro Fertilization in patients with low ovarian reserveIRCT20130603013566N13Vice chancellor for Research,Tabriz University Of Medical Sciences96
Not yet recruiting
Not Applicable
Effects of growth hormone (GH) replacement therapy in GH deficient adult childhood cancer survivors on organ size and microvascularisation of kidney and skin.growth hormone deficiency1002111210038430NL-OMON33094ovo Nordisk50
Active, not recruiting
Phase 1
Treatment of Growth Hormone Deficiency in patient with Chronic Heart FailureGrowth Hormone Deficiency associated with Chronic Heart FailureMedDRA version: 20.0Level: PTClassification code 10056438Term: Growth hormone deficiencySystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2016-004580-39-ITAOU FEDERICO II64
Active, not recruiting
Not Applicable
Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism - GH and androgens in protein catabolismChronic treatment with glucocorticoids (GCs) regardless of indication leads to marked protein catabolism that causes substantial debilitation which includes muscle wasting, weakness, skin fragility, bruising, poor wound healing and osteoporosis. The selection of subjects is therefore patients with polymyalgia rheumatica or inflammatory arthitis receiving long-term GC treatment.EUCTR2005-003750-10-SEVästraGötaland12